专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100004316A1 MULTIFUNCTIONAL CARRIERS FOR THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF 审中-公开
标题翻译：用于递送核酸的多功能载体及其使用方法
公开(公告)号：US20100004316A1
公开(公告)日：2010-01-07
申请号：US12443002
申请日：2007-09-27
申请人： Zheng-Rong Lu , Xu-Li Wang
发明人： Zheng-Rong Lu , Xu-Li Wang
IPC分类号： A61K48/00 , A61K31/713 , C07K14/00 , C12N5/00
CPC分类号： C07K14/003 , A61K47/543 , A61K47/60 , A61K47/62 , A61K47/6929 , C07K5/0606 , C12N15/87
摘要： Described herein are multifunctional compounds useful as devices for the delivery of nucleic acids to cells. Also described herein are methods for using the multifunctional compounds.
摘要翻译：本文描述了可用作将核酸递送至细胞的装置的多官能化合物。本文还描述了使用多官能化合物的方法。

2. 发明申请

US20090104143A1 Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells 审中-公开
标题翻译：含有透明质酸的生物缀合物：将抗癌药物靶向递送至癌细胞
公开(公告)号：US20090104143A1
公开(公告)日：2009-04-23
申请号：US12290879
申请日：2008-11-03
申请人： Yi Luo , Glenn D. Prestwich , Jindrich Kopecek , Zheng-Rong Lu
发明人： Yi Luo , Glenn D. Prestwich , Jindrich Kopecek , Zheng-Rong Lu
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： A61K31/74 , A61K31/704 , A61K41/00 , A61K47/58 , A61K47/61 , A61K47/65 , A61K2300/00
摘要： A cell-targeted polymeric drug delivery system was designed based on the specific interaction between hyaluronic acid (HA) and its cell surface receptors overexpressed on cancer cell surface. The invention relates to compounds composed of a carrier molecule, wherein the carrier molecule contains at least one residue of an anti-cancer agent and at least one residue of a hyaluronic acid. The invention also relates to methods of making and using the compounds thereof.
摘要翻译：基于透明质酸（HA）与其在癌细胞表面上过表达的细胞表面受体之间的特异性相互作用设计了基于细胞的聚合物药物递送系统。本发明涉及由载体分子组成的化合物，其中载体分子含有至少一种抗癌剂残基和至少一种透明质酸残基。本发明还涉及制备和使用其化合物的方法。

3. 发明授权

US06982324B1 Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof 失效
标题翻译：可降解大分子磁共振成像造影剂及其方法
公开(公告)号：US06982324B1
公开(公告)日：2006-01-03
申请号：US10288618
申请日：2002-11-05
申请人： Zheng-Rong Lu , Jindrich Kopecek , Dennis L. Parker
发明人： Zheng-Rong Lu , Jindrich Kopecek , Dennis L. Parker
IPC分类号： C07F5/00
CPC分类号： A61K49/128 , A61K49/04 , A61K49/085 , A61K49/146 , A61K51/065 , C07C323/41 , C08G73/0233 , C08G73/028
摘要： Novel degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are disclosed. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.
摘要翻译：公开了用于各种诊断程序的新型可降解大分子磁共振成像造影剂，以及用于合成，使用和降解这些试剂的方法。在本发明的各个方面公开的大分子造影剂是可降解的钆化合物，其表现出延长的血浆保留性，并且在实体瘤中增强的渗透性和保留性，但仍能够快速从体内清除。

4. 发明授权

US09011816B2 Fibronectin targeting contrast agent 有权
标题翻译：纤连蛋白靶向造影剂
公开(公告)号：US09011816B2
公开(公告)日：2015-04-21
申请号：US13071596
申请日：2011-03-25
申请人： Zheng-Rong Lu , Xueming Wu
发明人： Zheng-Rong Lu , Xueming Wu
IPC分类号： A61K51/00 , A61M36/14 , A61K49/14 , A61K49/12 , A61K51/06 , A61K51/08
CPC分类号： A61K49/14 , A61K49/124 , A61K51/065 , A61K51/088
摘要： Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.
摘要翻译：示例系统和方法增强MRI图像中的对比度。为了促进动脉粥样硬化斑块，动脉和静脉，心脏甚至肿瘤组织和纤维化的成像，纤维蛋白 - 纤连蛋白复合物或疾病相关的纤连蛋白特异性MRI造影剂（CLPD）对纤连蛋白具有特异性结合亲和力。

5. 发明申请

US20110236316A1 PEPTIDE TARGETING IMAGING AGENTS AND METHODS OF USE THEREOF 审中-公开
标题翻译：肽靶向成像剂及其使用方法
公开(公告)号：US20110236316A1
公开(公告)日：2011-09-29
申请号：US12919931
申请日：2009-02-27
申请人： Zheng-Rong Lu , Furong Ye
发明人： Zheng-Rong Lu , Furong Ye
IPC分类号： A61K49/00 , C07K7/64 , C07K7/06 , A61P43/00 , C12Q1/02
CPC分类号： A61K49/085 , A61K49/0017 , A61K49/0056 , A61K49/14 , A61K51/088
摘要： Described herein are peptide targeting imaging agents. The peptides are covalently attached to the imaging agent and have a specific peptide sequence that enables the imaging agent to accumulate specifically in tumor tissues. Additionally, the imaging agents are readily excreted by the subject within a short period of time after administration to the subject. Methods for using the imaging agents are also described herein.
摘要翻译：本文描述的是肽靶向成像剂。这些肽共价连接到成像剂上，并且具有能使成像剂在肿瘤组织中特异性积聚的特异性肽序列。此外，成像剂在给予受试者之后在短时间内容易地被受试者排出。本文还描述了使用成像剂的方法。

6. 发明申请

US20100284927A1 USE OF MRI CONTRAST AGENTS FOR EVALUATING THE TREATMENT OF TUMORS 审中-公开
标题翻译：使用MRI对比剂评估肿瘤治疗
公开(公告)号：US20100284927A1
公开(公告)日：2010-11-11
申请号：US12738856
申请日：2008-10-23
申请人： Zheng-Rong Lu , Yi Feng , Xueming Wu
发明人： Zheng-Rong Lu , Yi Feng , Xueming Wu
IPC分类号： A61K49/10
CPC分类号： A61K49/16 , A61B5/055 , A61K49/085 , A61K49/128
摘要： Described herein are methods for using macromolecular MRI contrast agents to evaluate the effectiveness of anti-cancer treatments. The methods take advantage of MRI for evaluating more specifically and accurately one or more tumor properties of the tumor in response to a particular treatment. Ultimately, the 5 methods described herein help evaluate the effectiveness of the anti-cancer treatment over time.
摘要翻译：本文描述了使用大分子MRI造影剂来评价抗癌治疗的有效性的方法。该方法利用MRI来更具体和准确地评估肿瘤响应于特定治疗的一种或多种肿瘤特性。最终，本文所述的5种方法有助于评估抗癌治疗随时间的有效性。

7. 发明申请

US20120244070A1 FIBRONECTIN TARGETING CONTRAST AGENT 有权
标题翻译： FIBRONECTIN针对对象代理
公开(公告)号：US20120244070A1
公开(公告)日：2012-09-27
申请号：US13071596
申请日：2011-03-25
申请人： Zheng-Rong LU , Xueming Wu
发明人： Zheng-Rong LU , Xueming Wu
IPC分类号： A61K49/14 , C07K7/06 , A61K51/08 , C07K7/64
CPC分类号： A61K49/14 , A61K49/124 , A61K51/065 , A61K51/088
摘要： Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.
摘要翻译：示例系统和方法增强MRI图像中的对比度。为了促进动脉粥样硬化斑块，动脉和静脉，心脏甚至肿瘤组织和纤维化的成像，纤维蛋白 - 纤连蛋白复合物或疾病相关的纤连蛋白特异性MRI造影剂（CLPD）对纤连蛋白具有特异性结合亲和力。

8. 发明授权

US07745590B1 Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof 有权
标题翻译：可降解大分子磁共振成像造影剂及其方法
公开(公告)号：US07745590B1
公开(公告)日：2010-06-29
申请号：US11203799
申请日：2005-08-15
申请人： Zheng-Rong Lu , Jindrich Kopecek , Dennis L. Parker
发明人： Zheng-Rong Lu , Jindrich Kopecek , Dennis L. Parker
IPC分类号： C07F5/00
CPC分类号： A61K49/14 , A61K49/128 , A61K49/146 , A61K49/16 , C07C323/41 , C08G73/0206 , C08G73/0233 , C08L79/02
摘要： Degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are described. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.
摘要翻译：描述了用于各种诊断程序的可降解的大分子磁共振成像造影剂，以及用于合成，使用和降解这些试剂的方法。在本发明的各个方面公开的大分子造影剂是可降解的钆化合物，其表现出延长的血浆保留性，并且在实体瘤中增强的渗透性和保留性，但仍能够快速从体内清除。

9. 发明申请

US20100135909A1 DENDRIMERS AND METHODS OF MAKING AND USING THEREOF 审中-公开
标题翻译：沉淀剂及其制备和使用方法
公开(公告)号：US20100135909A1
公开(公告)日：2010-06-03
申请号：US12377409
申请日：2007-08-16
申请人： Zheng-Rong Lu , Todd Kaneshiro
发明人： Zheng-Rong Lu , Todd Kaneshiro
IPC分类号： A61K49/00 , C08G77/38 , C08G63/91 , A61P43/00 , A61K47/48 , C12N5/00
CPC分类号： A61K49/0002 , A61K47/59 , A61K47/6455 , A61K49/124 , A61K51/065 , C08G83/003
摘要： A metal treatment composition including Tin (II) Chloride and processed montmorillonite clay. The addition of Tin (II) Chloride to the composition provides Tin for forming a ceramic-metal layer on the surfaces of the friction pair. Tin (II) Chloride provides Chlorine ions for forming Chloric films for protecting juvenile surfaces which form in the friction zone. The clay is heated and pulverized to produce a powder comprising both particles having crystalline layer structure and salts and oxides. The layered crystalline structure of the clay contains slip planes that transversely shift when tangential pressure from the friction pair is applied thereby lubricating the friction pair. The salts and oxides contribute to the formation of the ceramic-metal layer.
摘要翻译：一种金属处理组合物，包括氯化锡（II）和加工的蒙脱石粘土。向组合物中加入锡（II）氯化物提供锡，用于在摩擦副的表面上形成陶瓷 - 金属层。锡（II）氯化物提供氯离子用于形成氯膜以保护在摩擦区中形成的幼体表面。将粘土加热并粉碎以产生包含具有结晶层结构的颗粒和盐和氧化物的粉末。粘土的层状结晶结构包含滑动面，当施加来自摩擦副的切向压力时横向移动，从而润滑摩擦副。盐和氧化物有助于陶瓷 - 金属层的形成。

10. 发明申请

US20090076571A1 MRI-Guided Photodynamic Therapy For Cancer 审中-公开
标题翻译： MRI引导光动力治疗癌症
公开(公告)号：US20090076571A1
公开(公告)日：2009-03-19
申请号：US11792206
申请日：2005-12-02
申请人： Zheng-Rong Lu , Anagha Vaidya , Tianyi Ke
发明人： Zheng-Rong Lu , Anagha Vaidya , Tianyi Ke
IPC分类号： A61N5/06 , A61K49/00 , A61K49/06 , A61B5/055 , C07K2/00 , A61K49/14
CPC分类号： A61K49/085 , A61K41/0071 , A61K47/645 , A61K49/146
摘要： Disclosed is a method of therapy used in combination with a diagnostic tool for enhanced photodynamic therapy using MRI, called (magnetic resonance imaging)-guided photodynamic therapy. The methods of the present invention includes administration of MRI contrast agent labeled polymer photosensitizer conjugates, detection and localization of tumor or cancer tissues with contrast-enhanced MRI and specific illumination and treatment of localized target tissues, such as tumors or cancer cells, using laser energy. The delivered laser energy activates the photosensitizer accumulated in the target tissue, resulting in treatment. Also disclosed are novel conjugate compounds, such as PLGA-Mce6-DOTA-Gd complexes, having multi-functionality in that the complex may include an MRI contrasting agent linked to a photosensitizing agent.
摘要翻译：公开了一种治疗方法，与用于使用称为（磁共振成像） - 光导光疗法的MRI的增强光动力疗法的诊断工具结合使用。本发明的方法包括施用MRI造影剂标记的聚合物光敏剂缀合物，使用对比度增强的MRI和特定照明的肿瘤或癌组织的检测和定位以及使用激光能量的局部靶组织如肿瘤或癌细胞的治疗。递送的激光能量激活积聚在靶组织中的光敏剂，从而进行治疗。还公开了具有多功能性的新型缀合物化合物，例如PLGA-Mce6-DOTA-Gd复合物，因为该复合物可包括与光敏剂连接的MRI造影剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式